“We really try to meet them where they’re at in being able to convey what’s important about their technology and what they want to build as a company and then over the course of the relationship prepare them to tell that story to investors and the world at large,” she said. “There’s a meaningful role to be played as sort of a translator between the business and scientific fundamentals, and the story that people need to hear.”
Read MoreWe are proud to have Genoa’s partnership with Intabio recognized as a collaborative and differentiated way to empower our portfolio companies and drive to successful exits.
Read MoreOne-size-fits-all doesn’t work in medicine. This episode explains how doctors are now taking patients’ unique variables—like genetic makeup—into account when designing care.
Read MoreThe TechCrunch List is a verified, curated list of investors who have demonstrated a recent commitment to first checks and leading rounds from seed through growth, organized by market vertical.
Read MoreJenny Rooke of Genoa Ventures joins Nick Moran at The Full Ratchet to discuss Seed Investing at the Intersection of Biology & Technology.
Read MoreMarch is National Women’s Month with March 8 specifically designated as International Women’s Day. Although this is not remotely a comprehensive list, BioSpace recognizes these 10 women (in no particular order) as being especially influential in the biopharma industry.
Read MoreErik is joined by Jenny Rooke (@drjennyrooke), Managing Director at Genoa Ventures, and Jared Seehafer (@seehafer), Village Global Network Leader and CEO and co-founder of Enzyme.
Read MoreVenture capitalists see a steady stream of people asking for money and currying favor. This can inflate the ego to unhealthy proportions. The best VCs, however, don’t let all that get to their head. They also don’t just write checks. They help entrepreneurs.
Read MoreWe had the opportunity to speak with investor Jenny Rooke, PhD, managing director at 5 Prime Ventures to learn more about careers in synthetic biology outside of research and development.
Read MoreHere are several barriers to investing in synthetic biology that I’ve observed, drawing on comparisons to biotech investing more generally.
Read More
